IMRX

Immuneering Stock Analysis

AI Rating

Good
  • Quality1/10
  • Growth↑ 5/10
  • Value↑ 5/10
Immuneering sales and earnings growth
IMRX Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 46.19%
  • FCF Y/Y↑ 6.96%
Immuneering gross and profit margin trends
IMRX Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -440.48%
Immuneering net debt vs free cash flow
IMRX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Immuneering stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks